R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

A Horizon of hope: UPLIZNA data, NMOSD, and ECTRIMS

Neurological conditions like Multiple Sclerosis (MS) are an incredibly important area of research when it comes to drug discovery, but under that (sometim

JP Morgan

JPM2023: Breakthroughs await, but so do roadblocks

Editor-in-chief Jonah Comstock lays out a few of the most potent threads he heard in the conference centres, hotel rooms, and rain-soaked Lyfts of San Francisco.

R&D

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (

Digital